BISHOPS STORTFORD, UNITED KINGDOM – Dotmatics, a provider of informatics tools and scientific data management solutions to the international pharmaceutical and biotechnology industries, is very pleased to announce that it has licensed its entire Informatics suite to Lycera Corporation, including their own note book.

Stephen Gallagher, Chief Executive Officer of Dotmatics said “We have enjoyed an excellent working relationship with Lycera for the past couple of years, and we are very pleased that we can now provide them with our Informatics cloud and DBA solution.

Peter L. Toogood, Ph.D., Vice President, Chemistry and Chemical Biology said “We have found the Dotmatics database suite of software to be an extremely effective environment for sharing and analyzing data. The adoption of these solutions from Dotmatics constitutes an integral component of our research strategy. “

About Dotmatics

By enabling discovery organizations to share and use their research information more efficiently, the company’s aims are to facilitate the generation of strategic knowledge, making the right information available to the right person, at the right time and to boost customers’ productivity by maximizing their information and knowledge awareness across the spectrum of their discovery activities. We have now been able to add cloud computing to our offering, enabling our customers to become ever more efficient, by having informatics and DBA services based off-site.

About Lycera

Lycera Corp. is focused on the discovery and development of selective, small-molecule immunomodulators for the treatment of patients with autoimmune diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Lycera is developing drug candidates that target two novel therapeutic pathways and have the potential for first-in-class oral efficacy without the adverse effects of current standard-of-care antiproliferative and immunosuppressive agents. Lycera’s leading-edge technology platform and ATPase program are focused on the emerging area of cellular bioenergetics to selectively target and deplete pathologically activated cells. The company also has a lead program targeting the Th17 pathway through the inhibition of ROR-gamma. Lycera’s leadership team and advisors represent the core thought leaders in immunology, inflammation, organ transplantation and kinase biology and are responsible for key advances and discoveries in these fields. Founded in 2006, Lycera is headquartered in Cambridge, Mass. and has a state-of-the-art research center in Ann Arbor, Mich. Visit www.lycera.com for more information.

*Developed in collaboration with Astex Therapeutics.